Skip to main content
OpenTrials
Completed

NCT Number: NCT02657031

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

This study compares the efficacy of low dose Ketamine versus Compazine for the control of headache in patients presenting to the Emergency Department.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Medical Center of Southern Nevada

Las Vegas, Nevada, 89102, United States

About this study

After enrollment, each patient will randomized either to the standard treatment arm to receive prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV, OR to the study arm to receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. The diphenhydramine or ondansetron will be administered first, and immediately afterward the prochlorperazine or Ketamine will be administered. The prochlorperazine or Ketamine will be diluted in saline so that the total volume is 5 mL, and will be administered over 2 minutes. The diphenhydramine will be diluted in saline so that it is 2 mL (the same volume as the ondansetron). Both groups will also receive a 500 mL normal saline bolus after the study medications are administered. The ED pharmacist will be responsible for preparing the medications, using a double-blind protocol. He or she will record which arm the patient was randomized to. Only the pharmacist will have access to the randomization records and will not reveal the randomization until the end of the study. Emergency providers will be instructed not to administer any rescue medications for at least 30 minutes. The electronic medical record order will read "randomized study medication" (for the Ketamine or prochlorperazine) and "randomized add-on medication" (for the ondansetron or diphenhydramine).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 65 years
  • Temperature < 100.4° F
  • Diastolic Blood Pressure <104 mm Hg
  • Normal neurological exam and mormal mental status

Exclusion criteria

  • Pregnant or breastfeeding.
  • Meningeal signs are present
  • Acute angle closure glaucoma is suspected.
  • Head trauma within the previous two weeks
  • Lumbar puncture within the previous two weeks
  • Thunderclap onset of the headache
  • Weight more than 150 kg or less than 40 kg.
  • Known allergy to one of the study drugs.
  • History of schizophrenia or bipolar disorder.
  • History of intracranial hypertension.
  • Is a prisoner
  • Patient declined informed consent
  • Non-English speaking patient.
  • Attending provider excludes patient

Treatment and study plan

prochlorperazine

Drug

prochlorperazine 10 mg IV

Other names: Compazine

ketamine

Drug

Ketamine 0.3 mg/kg IV

Other names: Ketalar

diphenhydramine

Drug

Diphenhydromine 25 mg IV

Other names: Benadryl

ondansetron

Drug

Ondansetron 4 mg IV

Other names: Zofran

normal saline

Drug

Normal Saline 500 cc IV Bolus

Other names: NS

Primary outcomes

  1. Headache Following Intervention

    Time frame: 0-60 minutes

    Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication.

Secondary outcomes

  1. Anxiety

    Time frame: 0-60 minutes

    Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication.

  2. Nausea

    Time frame: 0-60 minutes

    Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication.

  3. The Number of Participants Experiencing Vomiting

    Time frame: 0-60 minutes

    Yes/No

  4. The Number of Patients Experiencing Restlessness

    Time frame: 0-60 minutes

    Yes/No

Sponsors and collaborators

Lead sponsor

University Medical Center of Southern Nevada

Other

Registry information

Official study title

The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jan 15, 2016
Registry last updated
Dec 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.